Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial for LAG-3 Inhibitor
Key Insights
LAG-3 is a key immune checkpoint molecule found on immune cells that can inhibit T cell function and allow tumors to evade immune system attack.
Preclinical studies suggest that combining LAG-3 and PD-1 inhibition may enhance anti-tumor immune responses beyond PD-1 blockade alone.
Bristol Myers Squibb (search) is evaluating relatlimab in combination with other agents across multiple tumor types to potentially expand treatment options.
Bristol Myers Squibb (search) (BMS) has provided an update on its ongoing research into LAG-3 (Lymphocyte-activation gene 3) inhibition as a novel immunotherapy approach for cancer treatment.
LAG-3 is an important immune checkpoint molecule expressed on several types of immune cells, including CD4+ and CD8+ T cells, regulatory T cells (Tregs), and natural killer (NK) cells. When activated, LAG-3 acts as a brake on the immune system by reducing T cell function and activation, potentially allowing tumors to escape immune surveillance.
Preclinical research has demonstrated that blocking LAG-3 may help restore anti-tumor immune responses. The combination of LAG-3 and PD-1 inhibition appears particularly promising, with data suggesting this dual checkpoint blockade could provide enhanced anti-tumor activity compared to PD-1 inhibition alone.
The company's LAG-3 inhibitor relatlimab is currently being evaluated in clinical trials in combination with various therapeutic agents across multiple tumor types. This broad development program aims to determine optimal combination approaches and identify patient populations most likely to benefit from LAG-3-targeted therapy.
Melanoma (search) Focus One key area of investigation is melanoma, where immunotherapy has already transformed treatment outcomes. Melanoma remains a significant health concern, with the World Health Organization projecting global incidence to reach 424,102 cases and 94,308 deaths by 2035. While early-stage melanoma is generally treatable, survival rates decline significantly in advanced disease.
Clinical Development Status The Phase 3 RELATIVITY-098 (search) trial is evaluating relatlimab-based treatment in melanoma (search). This study builds on previous research suggesting the potential benefits of targeting both LAG-3 and PD-1 pathways. The combination of nivolumab (anti-PD-1) and relatlimab has already received FDA approval under the brand name Opdualag for treating unresectable or metastatic melanoma in patients 12 years and older.
Safety Considerations As with other immunotherapies, careful monitoring of immune-mediated adverse reactions is essential. These can affect multiple organ systems and require prompt identification and management. Common adverse reactions observed with Opdualag include musculoskeletal pain, fatigue, rash, and immune-mediated effects on various organs.
Future Directions BMS continues to explore the potential of LAG-3 inhibition across different cancer types and treatment combinations. This research represents part of the company's broader commitment to advancing cancer immunotherapy through targeting novel immune checkpoints and developing innovative combination approaches.